152 related articles for article (PubMed ID: 36638600)
1. Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review.
Miglietta F; Fabi A; Generali D; Dieci MV; Arpino G; Bianchini G; Cinieri S; Conte PF; Curigliano G; De Laurentis M; Del Mastro L; De Placido S; Gennari A; Puglisi F; Zambelli A; Perrone F; Guarneri V
Cancer Treat Rev; 2023 Mar; 114():102511. PubMed ID: 36638600
[TBL] [Abstract][Full Text] [Related]
2. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study.
Dirix LY; Takacs I; Jerusalem G; Nikolinakos P; Arkenau HT; Forero-Torres A; Boccia R; Lippman ME; Somer R; Smakal M; Emens LA; Hrinczenko B; Edenfield W; Gurtler J; von Heydebreck A; Grote HJ; Chin K; Hamilton EP
Breast Cancer Res Treat; 2018 Feb; 167(3):671-686. PubMed ID: 29063313
[TBL] [Abstract][Full Text] [Related]
3. Emerging strategies: PARP inhibitors in combination with immune checkpoint blockade in BRCA1 and BRCA2 mutation-associated and triple-negative breast cancer.
Gupta T; Vinayak S; Telli M
Breast Cancer Res Treat; 2023 Jan; 197(1):51-56. PubMed ID: 36318381
[TBL] [Abstract][Full Text] [Related]
4. Optimizing the management of HER2-negative metastatic breast cancer in the era of PARP inhibitors-proceedings from breast cancer expert group meeting.
Dawood S; Konstantinova M; Perazzo F; Kim SB; Villarreal-Garza C; Franco SX; Simon SD; El-Nahas T
Chin Clin Oncol; 2020 Oct; 9(5):61. PubMed ID: 32819114
[TBL] [Abstract][Full Text] [Related]
5. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
Cortes J; Cescon DW; Rugo HS; Nowecki Z; Im SA; Yusof MM; Gallardo C; Lipatov O; Barrios CH; Holgado E; Iwata H; Masuda N; Otero MT; Gokmen E; Loi S; Guo Z; Zhao J; Aktan G; Karantza V; Schmid P;
Lancet; 2020 Dec; 396(10265):1817-1828. PubMed ID: 33278935
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update.
Moy B; Rumble RB; Come SE; Davidson NE; Di Leo A; Gralow JR; Hortobagyi GN; Yee D; Smith IE; Chavez-MacGregor M; Nanda R; McArthur HL; Spring L; Reeder-Hayes KE; Ruddy KJ; Unger PS; Vinayak S; Irvin WJ; Armaghani A; Danso MA; Dickson N; Turner SS; Perkins CL; Carey LA
J Clin Oncol; 2021 Dec; 39(35):3938-3958. PubMed ID: 34324366
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial.
Winer EP; Lipatov O; Im SA; Goncalves A; Muñoz-Couselo E; Lee KS; Schmid P; Tamura K; Testa L; Witzel I; Ohtani S; Turner N; Zambelli S; Harbeck N; Andre F; Dent R; Zhou X; Karantza V; Mejia J; Cortes J;
Lancet Oncol; 2021 Apr; 22(4):499-511. PubMed ID: 33676601
[TBL] [Abstract][Full Text] [Related]
8. Clinical Outcomes, Treatment Patterns, and Health Resource Utilization Among Metastatic Breast Cancer Patients with Germline BRCA1/2 Mutation: A Real-World Retrospective Study.
Quek RGW; Mardekian J
Adv Ther; 2019 Mar; 36(3):708-720. PubMed ID: 30656571
[TBL] [Abstract][Full Text] [Related]
9. Treatment patterns, clinical outcomes, health resource utilization, and cost in patients with BRCA-mutated metastatic breast cancer treated in community oncology settings.
Houts AC; Olufade T; Shenolikar R; Walker MS; Schwartzberg LS
Cancer Treat Res Commun; 2019; 19():100121. PubMed ID: 30785027
[TBL] [Abstract][Full Text] [Related]
10. Clinical Correlations of Programmed Cell Death Ligand 1 Status in Liquid and Standard Biopsies in Breast Cancer.
Jacot W; Mazel M; Mollevi C; Pouderoux S; D'Hondt V; Cayrefourcq L; Bourgier C; Boissiere-Michot F; Berrabah F; Lopez-Crapez E; Bidard FC; Viala M; Maudelonde T; Guiu S; Alix-Panabières C
Clin Chem; 2020 Aug; 66(8):1093-1101. PubMed ID: 32712650
[TBL] [Abstract][Full Text] [Related]
11. PARP (Poly ADP-Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer.
Taylor AM; Chan DLH; Tio M; Patil SM; Traina TA; Robson ME; Khasraw M
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011395. PubMed ID: 33886122
[TBL] [Abstract][Full Text] [Related]
12. Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review.
Li CH; Karantza V; Aktan G; Lala M
Breast Cancer Res; 2019 Dec; 21(1):143. PubMed ID: 31842957
[TBL] [Abstract][Full Text] [Related]
13. Emerging combination immunotherapy strategies for breast cancer: dual immune checkpoint modulation, antibody-drug conjugates and bispecific antibodies.
Torres ETR; Emens LA
Breast Cancer Res Treat; 2022 Jan; 191(2):291-302. PubMed ID: 34716871
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of mutations in BRCA and homologous recombination repair genes and real-world standard of care of Asian patients with HER2-negative metastatic breast cancer starting first-line systemic cytotoxic chemotherapy: subgroup analysis of the global BREAKOUT study.
Koh SJ; Ohsumi S; Takahashi M; Fukuma E; Jung KH; Ishida T; Dai MS; Chang CH; Dalvi T; Walker G; Bennett J; O'Shaughnessy J; Balmaña J
Breast Cancer; 2022 Jan; 29(1):92-102. PubMed ID: 34467476
[TBL] [Abstract][Full Text] [Related]
15. PARP-inhibitors for BRCA1/2-related advanced HER2-negative breast cancer: A meta-analysis and GRADE recommendations by the Italian Association of Medical Oncology.
Miglietta F; Cinquini M; Dieci MV; Cortesi L; Criscitiello C; Montemurro F; Del Mastro L; Zambelli A; Biganzoli L; Levaggi A; Delle Piane C; Marchiò C; Calabrese M; Fortunato L; Franco P; Meduri B; Fittipaldo VA; Gori S
Breast; 2022 Dec; 66():293-304. PubMed ID: 36379199
[TBL] [Abstract][Full Text] [Related]
16. Comparative prognostic analysis for triple-negative breast cancer with metaplastic and invasive ductal carcinoma.
Li Y; Zhang N; Zhang H; Yang Q
J Clin Pathol; 2019 Jun; 72(6):418-424. PubMed ID: 30872384
[TBL] [Abstract][Full Text] [Related]
17. Metastatic triple-negative breast cancer: Established and emerging treatments.
Puri A; Reddy TP; Patel TA; Chang JC
Breast J; 2020 Sep; 26(9):1793-1796. PubMed ID: 32578306
[TBL] [Abstract][Full Text] [Related]
18. Novel Therapies for Metastatic Triple-Negative Breast Cancer: Spotlight on Immunotherapy and Antibody-Drug Conjugates.
Nagayama A; Vidula N; Bardia A
Oncology (Williston Park); 2021 May; 35(5):249-254. PubMed ID: 33983696
[TBL] [Abstract][Full Text] [Related]
19. Combined immunotherapy for metastatic triple-negative breast cancer based on PD-1/PD-L1 immune checkpoint blocking.
He R; Yuan X; Chen Z; Zheng Y
Int Immunopharmacol; 2022 Dec; 113(Pt B):109444. PubMed ID: 36402069
[TBL] [Abstract][Full Text] [Related]
20. PD-1/PD-L1 immune checkpoint inhibitors in metastatic triple-negative breast cancer: a systematic review and meta-analysis.
Yu Y; Jin X; Zhu X; Xu Y; Si W; Zhao J
Front Immunol; 2023; 14():1206689. PubMed ID: 37377959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
